文献速递淋巴瘤浆细胞疾病造血干细胞移植与细胞治疗

同种异体CAR-T细胞疗法在浆细胞与淋巴系统恶性肿瘤中的前景与挑战

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
PubMed 文献 · Br J Haematol · 2021-10-21

综述指出,自体CAR-T制备流程复杂,同种异体(allo-CAR)「现货型」产品可规避这些限制。早期临床试验结果积极,但存在移植物抗宿主病、排斥、免疫原性、体内持久性不明及产量等障碍。文章系统回顾了allo-CAR在B细胞与浆细胞恶性肿瘤中的平台与挑战。

要点

  • allo-CAR可规避自体CAR-T的采集、制造与物流复杂性。
  • 主要障碍包括GVHD、供者T细胞排斥、免疫原性及体内持久性未知。
  • 早期临床试验结果积极,但需克服上述挑战才能广泛使用。

核心结论

  • 同种异体CAR-T早期结果积极,但需克服GVHD、排斥、免疫原性、持久性未知和产量等障碍才能广泛应用。

研究设计与样本

  • 综述文章,回顾自体CAR-T的挑战、allo-CAR的获益与潜在挑战,以及B细胞和浆细胞恶性肿瘤的allo-CAR平台。

主要发现

  • 自体CAR-T需患者合格性评估、单采能力、复杂制造和运输物流等多环节协调。
  • allo-CAR可规避自体CAR-T的许多问题,多个产品正进入临床试验,早期结果积极。
  • allo-CAR的主要障碍包括移植物抗宿主病和供者T细胞排斥,其他包括免疫原性、体内持久性未知和CAR-T产量。

临床怎么用

  • 血液科医生应了解allo-CAR作为现货型产品的潜力,同时关注GVHD和排斥等风险。

局限性

  • 综述未报告具体样本量、疗效数值或安全性比例,早期临床试验数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy in haematological malignancies. However, the currently approved products are generated from autologous T cells that require orchestration of several logistically complex steps, which include patient eligibility, apheresis capability, complex manufacturing processes and shipping logistics. Use of third-party donor-derived (allogeneic) effector cells that allows the generation of 'off-the-shelf" CAR T cells (allo-CAR) could circumvent many of the problems associated with autologous CAR T-cell therapy. Several allogeneic products are entering clinical trials, and though early, the results look promising. The recognised potential benefits of allo-CAR do not come without significant challenges, that must be overcome for their widespread use. Alloreactivity, i.e. graft-versus-host disease (GVHD), and rejection of donor T cells is one of the major barriers, while other potential barriers include immunogenicity, unknown in vivo persistence, and CAR T-cell yield. In the present review, we provide a comprehensive review of the challenges associated with autologous CAR, the benefits and potential challenges associated with allo-CAR. Finally, we review the available platforms for allo-CAR for B-cell and plasma cell malignancies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dhakal B, Chhabra S, Savani BN, et al. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. Br J Haematol. 2021. PMID: 34671973. doi:10.1111/bjh.17904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。